Medicine
Viltepso 250 mg injection
Viltepso 250 mg injection is a prescription medicine containing Viltolarsen for intravenous use, marketed by NS Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store VILTEPSO at 2°C to 8°C (36°F to 46°F). Do not freeze.
Key facts
- Active ingredient (INN)
- Viltolarsen
- Brand
- Viltepso
- Strength
- 250 mg
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- NS Pharma
- Manufacturer
- NS Pharma
- Origin register
- US FDA, United States
- Storage
- Store VILTEPSO at 2°C to 8°C (36°F to 46°F). Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 August 2020
- Identifiers
- DailyMed set ID 1ffff9a8-6d6a-4dcb-8493-1b6cc3a5d123NDC 73292-011Application NDA212154
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 1 injection, solution in 1 vial, glass | 73292-011-01 | NS Pharma | 13 August 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 12 August 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Viltolarsen is a prescription medicine indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. MedsAcross supplies Viltolarsen for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ViltolarsenFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Viltepso prescribing information (NS Pharma) · U.S. National Library of Medicine, DailyMed
Need Viltepso 250 mg injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.